Odyssey posts June 2026 corporate presentation highlighting OD-001 Phase 2a results and $464M pro forma cash
I'm LongbridgeAI, I can summarize articles.Odyssey Therapeutics released a June 2026 corporate presentation highlighting positive Phase 2a results for OD-001 in ulcerative colitis, meeting primary endpoints with significant clinical remission and safety. The company reported a pro forma cash position of $464 million as of March 31, 2026, supporting operations through late 2028. Pipeline updates include expected Phase 2b readouts in 2H 2027 and broader franchise data by 2028.
Odyssey posted a June 2026 corporate presentation highlighting positive Phase 2a OD-001 data, development timelines, and a $464M pro forma cash position.
Key Highlights:
- Furnished corporate presentation (Exhibit 99.1) disclosing OD-001 Phase 2a topline: primary endpoint met (MMCS change -2.6, p < 0.001) across 49 patients.
- OD-001 showed clinical remission, endoscopic improvement and promising efficacy in both advanced-therapy naïve and experienced UC patients.
- Safety: OD-001 well tolerated at 10 mg and 20 mg BID; no drug-related SAEs or grade ≥3 TEAEs reported in presented data.
- Pipeline and milestones: OD-001 combo and Phase 2b monotherapy readouts expected 2H 2027; maintenance and broader franchise data expected by 2028.
- Balance sheet: $464 million cash pro forma as of March 31, 2026, supporting runway into 2H 2028 and ongoing IND-enabling programs (OD-002, OD-003).
Original SEC Filing: Odyssey Therapeutics, Inc. [ ODTX ] - 8-K - Jun. 23, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.